Next Investors logo grey
  1. Home
  2. Biotechnology

Biotechnology

Investing in Early-Stage Biotechs and the Drill Race is on...

Next Investors Sep 09, 2023

In this Weekender, we look at the high-risk, high-reward landscape of biotech investing, early-stage companies offer outsized returns on successful clinical trials, aligning perfectly with our investment strategy and providing a unique opportunity to contribute to groundbreaking advancements in medical science.

How the mainstream news shapes the macro themes we invest in

Next Investors Jan 28, 2023

In this weekly wrap, we look at the various outlooks presented by the media toward our key investment themes such as; biotechs, resources and technology companies.

Pre-result build up? The “big catalyst” in 2023

Finfeed Sep 02, 2022

Our biotech Investment and 2021 Biotech Pick of the Year, Dimerix (ASX:DXB), has been busy this year working towards its all important Phase 3 trial and first interim results. After our initial entry at 20c in August 2021, our Investment in DXB is currently sitting below that price at 14.5 cents.

New Portfolio Addition: Arovella Therapeutics

Finfeed Feb 18, 2022

Today we are finally announcing a new investment in the Next Investors portfolio. Arovella Therapeutics (ASX:ALA) is a small ASX biotech going after a unique solution to the scourge of cancer - with cutting edge technology licensed from some of the foremost cancer research institutions - and has attracted big names to the project.

New Portfolio Addition: Arovella Therapeutics

Next Investors Feb 18, 2022

Today we are finally announcing a new investment in the Next Investors portfolio. Arovella Therapeutics (ASX:ALA) is a small ASX biotech going after a unique solution to the scourge of cancer - with cutting edge technology licensed from some of the foremost cancer research institutions - and has attracted big names to the project.

Earlier than Expected - DXB Gets First Regulatory Approval in Europe.

Finfeed Feb 01, 2022

Dimerix (ASX:DXB) just delivered significant progress on its Phase III Clinical Trial for FSGS, with the first EU regulatory approval given for DXB’s kidney disease study in Denmark... earlier than expected.

Introducing: Our Biotech Pick of the Year 2021

Next Investors Aug 16, 2021

Today we announce the fourth addition to our portfolio for 2021. Today we are adding Dimerix (ASX:DXB) to the Next Investors portfolio as our inaugural Biotech Pick of the Year for 2021.

$2.6M Capped eSense-Lab Signs US$600k Revenue Deal

Next Investors Archived Jun 19, 2020

Backed by a new leadership team, ASX-listed biotech junior, eSense-Lab (ASX:ESE) is implementing a new business model that sees it enter joint venture (JV) agreements to quickly reach multiple revenue-generating markets.

eSense-Lab strikes JV to develop and a sell new range of terpene products

Finfeed Archived Jun 15, 2020

eSense-Lab Limited (ASX: ESE) has entered a JV with ANC Enterprises to provide specific terpenes uniquely developed for a range of skin care, hair care and hand sanitiser products. ANC will formulate and manufacture the resulting products containing ESE’s proprietary terpene mixes.
Page 1 of 9 next >

Join Our
Mailing List